TY - JOUR
T1 - Vergence/accommodative therapy for symptomatic convergence insufficiency in children
T2 - Time course of improvements in convergence function
AU - the Convergence Insufficiency Treatment Trial – Attention and Reading Trial (CITT-ART) Investigator Group
AU - Jenewein, Erin C.
AU - Cotter, Susan
AU - Roberts, Tawna
AU - Kulp, Marjean
AU - Mitchell, G. Lynn
AU - Jones-Jordan, Lisa A.
AU - Chen, Angela M.
AU - Hopkins, Kristine
AU - Huang, Kristine
AU - Amster, Deborah
AU - Fecho, Gregory
AU - Tyler, Julie
AU - Meiyeppen, Shivakhaami
AU - Scheiman, Mitchell
AU - Cooper, Jeffrey
AU - Schulman, Erica
AU - Hamian, Kimberly
AU - Iacono, Danielle
AU - Larson, Steven
AU - Leung, Valerie
AU - Meeder, Sara
AU - Ramos, Elaine
AU - Ritter, Steven
AU - Steiner, Audra
AU - Stormann, Alexandria
AU - Vricella, Marilyn
AU - Zhu, Xiaoying
AU - Tamkins, Susanna
AU - Aguilera, Naomi
AU - Brafman, Elliot
AU - Capo, Hilda
AU - Cavuoto, Kara
AU - Crespo, Isaura
AU - Dowling, Monica
AU - Draskovic, Kristie
AU - Farag, Miriam
AU - Fischer, Vicky
AU - Grace, Sara
AU - Gutierrez, Ailen
AU - Manchola-Orozco, Carolina
AU - Martinez, Maria
AU - McKeown, Craig
AU - Osigian, Carla
AU - Pham, Tuyet Suong
AU - Small, Leslie
AU - Townsend, Natalie
AU - Gallaway, Michael
AU - Boas, Mark
AU - Calvert, Christine
AU - Kratochvil, Christopher J.
N1 - Funding Information:
This work was supported by National Eye Institute of National Institutes of Health, Department of Health and Human Services (Grant number 5U10EY022599 to MMS, 5U10EY022601 to GLM, 5U10EY022595 to SC, 5U10EY022592 to MK, 5U10EY022586 to ES, 5U10EY022600 to RH, 5U10EY022587 to MG, 5U10EY022596 to RC, 5U10EY022594 to KH, and 5U10EY022591 to ST). The funding organisation had no role in the design or conduct of this research. Meeting presentation: This manuscript was presented in part at the American Academy of Optometry Annual Meeting (November 2019 in Orlando, FL).
Publisher Copyright:
© 2022 College of Optometrists.
PY - 2023/1
Y1 - 2023/1
N2 - Purpose: To evaluate the time course of improvements in clinical convergence measures for children with symptomatic convergence insufficiency treated with office-based vergence/accommodative therapy. Methods: We evaluated convergence measures from 205, 9- to 14-year-old children with symptomatic convergence insufficiency randomised to office-based vergence/accommodative therapy in the Convergence Insufficiency Treatment Trial – Attention and Reading Trial (CITT-ART). Near-point of convergence (NPC) and near-positive fusional vergence (PFV) were measured at baseline and after 4, 8, 12 and 16 weeks of therapy; mean change in NPC and PFV between these time points were compared using repeated measures analysis of variance. Rates of change in NPC and PFV from: (1) baseline to 4 weeks and (2) 4–16 weeks were calculated. For each time point, the proportion of participants to first meet the normal criterion for NPC (<6 cm), PFV blur (break if no blur; >15Δ and >2 times the exodeviation) and convergence composite (NPC and PFV both normal) were calculated. Results: The greatest change in NPC and PFV (7.6 cm and 12.7 Δ) and the fastest rate of improvement in NPC and PFV (1.9 cm/week and 3.2 Δ/week, respectively) were both found during the first 4 weeks of therapy, with both slowing over the subsequent 12 weeks. After 12 weeks of therapy, the NPC, PFV and convergence composite were normal in 93.2%, 91.7% and 87.8% of participants, respectively, and normalised with another 4 weeks of therapy in 4.4%, 2.0% and 4.4% of participants, respectively. Conclusion: Although the greatest improvements in NPC and PFV occurred in the first 4 weeks of therapy, most participants had weekly improvements over the subsequent 12 weeks of treatment. While most children with convergence insufficiency obtained normal convergence following 12 weeks of therapy, an additional 4 weeks of vergence/accommodative therapy may be beneficial for some participants.
AB - Purpose: To evaluate the time course of improvements in clinical convergence measures for children with symptomatic convergence insufficiency treated with office-based vergence/accommodative therapy. Methods: We evaluated convergence measures from 205, 9- to 14-year-old children with symptomatic convergence insufficiency randomised to office-based vergence/accommodative therapy in the Convergence Insufficiency Treatment Trial – Attention and Reading Trial (CITT-ART). Near-point of convergence (NPC) and near-positive fusional vergence (PFV) were measured at baseline and after 4, 8, 12 and 16 weeks of therapy; mean change in NPC and PFV between these time points were compared using repeated measures analysis of variance. Rates of change in NPC and PFV from: (1) baseline to 4 weeks and (2) 4–16 weeks were calculated. For each time point, the proportion of participants to first meet the normal criterion for NPC (<6 cm), PFV blur (break if no blur; >15Δ and >2 times the exodeviation) and convergence composite (NPC and PFV both normal) were calculated. Results: The greatest change in NPC and PFV (7.6 cm and 12.7 Δ) and the fastest rate of improvement in NPC and PFV (1.9 cm/week and 3.2 Δ/week, respectively) were both found during the first 4 weeks of therapy, with both slowing over the subsequent 12 weeks. After 12 weeks of therapy, the NPC, PFV and convergence composite were normal in 93.2%, 91.7% and 87.8% of participants, respectively, and normalised with another 4 weeks of therapy in 4.4%, 2.0% and 4.4% of participants, respectively. Conclusion: Although the greatest improvements in NPC and PFV occurred in the first 4 weeks of therapy, most participants had weekly improvements over the subsequent 12 weeks of treatment. While most children with convergence insufficiency obtained normal convergence following 12 weeks of therapy, an additional 4 weeks of vergence/accommodative therapy may be beneficial for some participants.
KW - convergence insufficiency
KW - near-point of convergence
KW - positive fusional vergence
KW - treatment kinetics
KW - vergence/accommodative therapy
UR - http://www.scopus.com/inward/record.url?scp=85140256934&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85140256934&partnerID=8YFLogxK
U2 - 10.1111/opo.13062
DO - 10.1111/opo.13062
M3 - Article
C2 - 36271753
AN - SCOPUS:85140256934
SN - 0275-5408
VL - 43
SP - 105
EP - 115
JO - Ophthalmic and Physiological Optics
JF - Ophthalmic and Physiological Optics
IS - 1
ER -